Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.
Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.
复制标题
重症肌无力:流行病学,病理生理学和临床表现。
DOI:
10.3390/jcm10112235
复制
发表时间:
2021-05-21
影响因子:
3.9
通讯作者:
Soliven B
中科院分区:
文献类型:
--
作者:
Dresser L;Wlodarski R;Rezania K;Soliven B
Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases per million person-years, and the prevalence rate ranges from 150 to 200 cases per million. MG is considered a classic example of antibody-mediated autoimmune disease. Most patients with MG have autoantibodies against the acetylcholine receptors (AChRs). Less commonly identified autoantibodies include those targeted to muscle-specific kinase (MuSK), low-density lipoprotein receptor-related protein 4 (Lrp4), and agrin. These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane. The core clinical manifestation of MG is fatigable muscle weakness, which may affect ocular, bulbar, respiratory and limb muscles. Clinical manifestations vary according to the type of autoantibody, and whether a thymoma is present.
登录
查看更多内容
影响因子:
9.9
作者:
Deymeer, F.;Gungor-Tuncer, O.;Saruhan-Direskeneli, G.
通讯作者:
Saruhan-Direskeneli, G.
影响因子:
9.9
作者:
CHIU, HC;VINCENT, A;HUNG, TP
通讯作者:
HUNG, TP
影响因子:
5.7
作者:
Bettini, Mariela;Chaves, Marcelo;Rugiero, Marcelo
通讯作者:
Rugiero, Marcelo
影响因子:
33.6
作者:
Albuquerque EX;Pereira EF;Alkondon M;Rogers SW
通讯作者:
Rogers SW
影响因子:
11.2
作者:
Cole, Rebecca N.;Reddel, Stephen W.;Phillips, William D.
通讯作者:
Phillips, William D.